ROCKET PHARMACEUTICALS, INC.

Listed Company

RCKTCIK 0001281895NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-223.12M

Total Assets

$330.45M

Equity

$277.22M

Shares Out

108.57M

Op. Cash Flow

$-190.01M

Business

ROCKET PHARMACEUTICALS, INC. is a fully integrated, late‑stage biotechnology company developing first‑in‑class in vivo and ex vivo gene therapies that target rare, often pediatric, monogenic diseases. Its main products are AAV‑based in vivo programs (e.g., Danon disease, PKP2‑ACM, BAG3‑DCM) and lentiviral ex vivo programs (e.g., LAD‑I, Fanconi anemia, pyruvate kinase deficiency). The company organizes its pipeline into cardiovascular and hematology programmatic segments and maintains cGMP manufacturing and licensing arrangements to support development and commercialization. It conducts clinical trials and seeks regulatory approvals across the U.S., European Union and other global markets with worldwide commercialization rights under license agreements.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0	0	0	0	0
Research and development	142	171	186	166	125
General and administrative	87	102	73	59	42
Restructuring	3	0	—	—	—
Total operating expenses	232	273	260	224	167
Loss from operations	−232	−273	−260	−224	−167
Interest expense	−2	−2	−2	−2	−3
Interest and other income, net	3	8	5	4	3
Accretion of discount on investments, net	7	8	11	−47,000	−3
Net loss	−223	−259	−246	−222	−169
Net loss per share - basic (in dollars per share)	−2.01	−2.73	−2.92	−3.26	−2.67
Net loss per share - diluted (in dollars per share)	−2.01	−2.73	−2.92	−3.26	−2.67
Weighted-average common shares outstanding - basic (in shares)	111	95	84	68	63
Weighted-average common shares outstanding - diluted (in shares)	111	95	84	68	63

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-03-31	FY 2022 2022-12-31
Cash and cash equivalents	78	164	56	—	141
Investments	111	209	317	—	216
Prepaid expenses and other current assets	4	6	5	—	8
Total current assets	193	378	378	—	364
Property and equipment, net	28	37	39	—	29
Goodwill	39	39	39	—	39
Intangible assets	25	25	25	—	26
Restricted cash	1	1	1	—	1
Deposits	482,000	529,000	533,000	—	608,000
Operating lease right-of-use assets, net	3	4	4	200,000	2
Finance lease right-of-use asset, net	40	42	45	—	47
Total assets	330	528	566	—	552
Accounts payable and accrued expenses	27	38	46	—	37
Operating lease liabilities, current	1	1	925,000	—	773,000
Finance lease liability, current	2	2	2	—	2
Total current liabilities	30	41	49	—	39
Operating lease liabilities, non-current	3	3	3	200,000	1
Finance lease liability, non-current	19	19	19	—	19
Other liabilities	1	1	3	—	3
Total liabilities	53	64	74	—	62
Commitments and contingencies (Note 14)	—	—	—	—	—
Common stock, $0.01 par value, 180,000,000 shares authorized; 108,319,783 and 106,453,818 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively	1	1	903,000	—	791,000
Additional paid-in capital	1,717	1,680	1,451	—	1,203
Accumulated other comprehensive (loss) income	−31,000	66,000	319,000	—	−357,000
Accumulated deficit	−1,440	−1,218	−959	—	−714
Total stockholders' equity	277	463	493	—	490
Total liabilities and stockholders' equity	330	528	566	—	552

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization of property and equipment	9	7	5	4	3
Amortization of finance lease right of use asset	2	2	2	2	2
Impairment of operating lease right-of-use asset	262,000	0	—	—	—
Stock-based compensation	37	44	39	31	29
Accretion of discount on investments, net	−7	−8	−10	134,000	3
Change in fair value of warrant liabilities	0	−2	−364,000	—	—
Prepaid expenses and other assets	2	−661,000	3	−4	1
Accounts payable and accrued expenses	−10	6	10	10	−5
Operating lease liabilities and right of use assets, net	45,000	89,000	137,000	−120,000	−11,000
Finance lease liability	35,000	95,000	139,000	172,000	201,000
Other liabilities	−81,000	81,000	705,000	−57,000	−56,000
Net cash used in operating activities	−190	−210	−195	−178	−121
Purchases of investments	−277	−246	−391	−376	−246
Proceeds from maturities of investments	381	383	309	273	272
Purchases of property and equipment	−440,000	−6	−16	−8	−8
Net cash provided by investing activities	104	132	−98	−69	19
Issuance of common stock pursuant to exercise of stock options	0	3	2	631,000	11
Return of related party short-swing profits	215,000	0	—	—	—
Repurchase of restricted stock units to satisfy tax withholding	−67,000	0	—	—	—
Net cash provided by financing activities	148,000	186	208	155	38
Net change in cash, cash equivalents and restricted cash	−86	108	−85	−92	−65
Accrued purchases of property and equipment, ending balance	0	185,000	1	2	728,000
Receivables from sale of property and equipment, ending balance	0	135,000	0	0	—
Operating lease liabilities	0	1	3	0	0
Operating lease right of use assets	0	1	3	0	—
Net unrealized loss on investments	−100,000	−300,000	700,000	−200,000	−100,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro